Search | New Scientist

23andMe has sold the rights to develop a drug based on its users’ DNA

10 January 2020

Consumer genomics firm 23andMe has signed its first deal to sell the rights to develop a new drug for inflammatory diseases to a pharmaceutical company

Sign up to our weekly newsletter

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers.

Subject

Section

Type

Topics

Author

Premium

23andMe has sold the rights to develop a drug based on its users’ DNA

Sign up to our weekly newsletter